Seong Hoon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seong Hoon Kim has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
Sang-Jae Park
Center for Liver Cancer, National Cancer Center, Goyang, Gyeonggi, South Korea
17 shared publicationsEung Chang Lee
National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Korea
15 shared publicationsSeung Duk Lee
Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea
14 shared publicationsSang Jae Park
Natl Canc Ctr, Ctr Organ Transplantat, 111 Jungbalsan Ro, Goyang Si 410769, Gyeonggi Do, South Korea
11 shared publications- Sang-Jae Park
Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea
10 shared publications Young Kyu Kim
8 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (31) , 3072
Postrecurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (31) , 3072
Postrecurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603
- Open Access
- 25 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 578
Machine Perfusion and Oncologic Outcomes After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Background: Machine perfusion has emerged as a promising strategy to attenuate ischemia–reperfusion injury during liver transplantation (LT). However, its impact on hepatocellular carcinoma (HCC) recurrence and post-transplant oncologic outcomes remains uncertain. We performed a systematic review and meta-analysis evaluating the association between machine perfusion and oncologic outcomes after LT for HCC. Methods: A systematic literature search of PubMed/MEDLINE, Embase, and Web of Science was conducted from database inception to May 2026. Comparative clinical studies evaluating machine perfusion and oncologic outcomes after LT for HCC were included. The primary outcome was recurrence-free survival (RFS). Secondary outcomes included HCC recurrence, early recurrence, overall survival (OS), and graft-related outcomes. Risk of bias was assessed using the ROBINS-I tool. Random-effects meta-analyses were performed when appropriate. Results: Six comparative clinical studies involving HCC recipients undergoing LT were included. All studies were observational, and no randomized controlled trial was identified. Three studies were judged to have a moderate risk of bias and three were judged to have a serious risk of bias. In the primary RFS meta-analysis, machine perfusion was associated with a numerically lower risk of recurrence or death, although the pooled estimate did not reach statistical significance (HR 0.34, 95% CI 0.07–1.77; p = 0.20). The binary recurrence analysis also demonstrated a numerically lower risk of HCC recurrence after machine perfusion (RR 0.40, 95% CI 0.13–1.20; p = 0.10). Several studies reported favorable associations between machine perfusion and early recurrence, while large adjusted cohorts reported associations with improved RFS and OS. Machine perfusion was generally associated with lower markers of ischemia–reperfusion injury, including postoperative aminotransferase release. Conclusions: Current evidence suggests a potential favorable association between machine perfusion and oncologic outcomes after LT for HCC. However, the pooled estimates from the primary analyses were not statistically significant, and the evidence remains limited by the small number of studies, observational designs, heterogeneity, and potential cohort overlap. Further prospective studies are required before an oncologic benefit of machine perfusion can be established.
- 25 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 578
Open AccessMachine Perfusion and Oncologic Outcomes After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Background: Machine perfusion has emerged as a promising strategy to attenuate ischemia–reperfusion injury during liver transplantation (LT). However, its impact on hepatocellular carcinoma (HCC) recurrence and post-transplant oncologic outcomes remains uncertain. We performed a systematic review and meta-analysis evaluating the association between machine perfusion and oncologic outcomes after LT for HCC. Methods: A systematic literature search of PubMed/MEDLINE, Embase, and Web of Science was conducted from database inception to May 2026. Comparative clinical studies evaluating machine perfusion and oncologic outcomes after LT for HCC were included. The primary outcome was recurrence-free survival (RFS). Secondary outcomes included HCC recurrence, early recurrence, overall survival (OS), and graft-related outcomes. Risk of bias was assessed using the ROBINS-I tool. Random-effects meta-analyses were performed when appropriate. Results: Six comparative clinical studies involving HCC recipients undergoing LT were included. All studies were observational, and no randomized controlled trial was identified. Three studies were judged to have a moderate risk of bias and three were judged to have a serious risk of bias. In the primary RFS meta-analysis, machine perfusion was associated with a numerically lower risk of recurrence or death, although the pooled estimate did not reach statistical significance (HR 0.34, 95% CI 0.07–1.77; p = 0.20). The binary recurrence analysis also demonstrated a numerically lower risk of HCC recurrence after machine perfusion (RR 0.40, 95% CI 0.13–1.20; p = 0.10). Several studies reported favorable associations between machine perfusion and early recurrence, while large adjusted cohorts reported associations with improved RFS and OS. Machine perfusion was generally associated with lower markers of ischemia–reperfusion injury, including postoperative aminotransferase release. Conclusions: Current evidence suggests a potential favorable association between machine perfusion and oncologic outcomes after LT for HCC. However, the pooled estimates from the primary analyses were not statistically significant, and the evidence remains limited by the small number of studies, observational designs, heterogeneity, and potential cohort overlap. Further prospective studies are required before an oncologic benefit of machine perfusion can be established.
- Open Access
Oncologic Outcomes After ABO-Incompatible Versus Compatible Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Background: ABO-incompatible living-donor liver transplantation (ABOi LDLT) can expand the donor pool for patients with hepatocellular carcinoma (HCC), but concerns remain regarding tumor recurrence and long-term survival. Methods: A systematic review and meta-analysis was performed according to PRISMA 2020. PubMed, Embase, and Web of Science were searched. Comparative studies evaluating oncologic outcomes after ABOi versus ABO-compatible (ABOc) LDLT for HCC were included in the quantitative synthesis; non-comparative studies were included in the qualitative synthesis. Hazard ratios (HRs) for recurrence-free survival (RFS) and overall survival (OS) were pooled using a random-effects model. When HRs were not directly reported, they were estimated from Kaplan–Meier curves using established methods. Results: Sixteen reports were screened, 12 full-text articles were assessed, and 8 studies were included in the systematic review. Three comparative single-center cohort studies were eligible for meta-analysis. Pooled analysis showed no significant difference between ABOi and ABOc LDLT for RFS (HR 1.07, 95% confidence interval [CI] 0.77–1.49; I2 = 0%) or OS (HR 1.08, 95% CI 0.74–1.57; I2 = 0%). Five additional studies were synthesized qualitatively, suggesting that recurrence risk may be influenced more by tumor biology and peri-transplant management, including desensitization intensity and immunosuppression exposure, than by ABO incompatibility itself. Conclusions: Current limited comparative evidence does not demonstrate inferior RFS or OS after ABOi LDLT in carefully selected patients with HCC. Larger multicenter comparative studies with standardized reporting of tumor biology, desensitization protocols, and immunosuppression exposure are warranted to confirm these findings and clarify protocol-related effects on post-transplant recurrence.
Open AccessOncologic Outcomes After ABO-Incompatible Versus Compatible Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Background: ABO-incompatible living-donor liver transplantation (ABOi LDLT) can expand the donor pool for patients with hepatocellular carcinoma (HCC), but concerns remain regarding tumor recurrence and long-term survival. Methods: A systematic review and meta-analysis was performed according to PRISMA 2020. PubMed, Embase, and Web of Science were searched. Comparative studies evaluating oncologic outcomes after ABOi versus ABO-compatible (ABOc) LDLT for HCC were included in the quantitative synthesis; non-comparative studies were included in the qualitative synthesis. Hazard ratios (HRs) for recurrence-free survival (RFS) and overall survival (OS) were pooled using a random-effects model. When HRs were not directly reported, they were estimated from Kaplan–Meier curves using established methods. Results: Sixteen reports were screened, 12 full-text articles were assessed, and 8 studies were included in the systematic review. Three comparative single-center cohort studies were eligible for meta-analysis. Pooled analysis showed no significant difference between ABOi and ABOc LDLT for RFS (HR 1.07, 95% confidence interval [CI] 0.77–1.49; I2 = 0%) or OS (HR 1.08, 95% CI 0.74–1.57; I2 = 0%). Five additional studies were synthesized qualitatively, suggesting that recurrence risk may be influenced more by tumor biology and peri-transplant management, including desensitization intensity and immunosuppression exposure, than by ABO incompatibility itself. Conclusions: Current limited comparative evidence does not demonstrate inferior RFS or OS after ABOi LDLT in carefully selected patients with HCC. Larger multicenter comparative studies with standardized reporting of tumor biology, desensitization protocols, and immunosuppression exposure are warranted to confirm these findings and clarify protocol-related effects on post-transplant recurrence.
- Open Access
- 12 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1087
Efficacy and Safety of a Bioinspired Chitosan–Catechol/Gelatin Hemostatic Patch vs. TachoSil in Hepatectomy: A Randomized Noninferiority Trial
Background/Objectives: Topical hemostatic biomaterials are used to control diffuse parenchymal bleeding during hepatectomy. TachoSil is a widely used standard fibrin sealant patch. We evaluated the efficacy and safety of InnoSEAL Plus DL, a novel bioinspired absorbable chitosan–catechol/gelatin hemostatic patch, compared with TachoSil. Methods: This multicenter, randomized, single-blind, active-controlled, parallel-group noninferiority trial enrolled adults undergoing hepatectomy who had persistent oozing from the hepatic transection surface despite primary hemostasis. Participants were randomized in a 1:1 ratio to receive InnoSEAL Plus DL or TachoSil. The primary endpoint was hemostatic success within 3 min of application, with a prespecified noninferiority margin of −19.4 percentage points (pp). Safety was assessed up to 30 days postoperatively. Results: Ninety patients were randomized (45 per group). In the per-protocol population, 3 min hemostatic success was achieved in 100.0% of both the InnoSEAL Plus DL (43/43) and TachoSil (41/41) groups. The risk difference was 0.0 pp, and the lower bound of the one-sided 97.5% confidence interval was −8.2 pp, confirming noninferiority. The mean time to hemostasis was similar between groups (1.2 vs. 1.3 min), and no intraoperative rebleeding occurred. Adverse events were reported in 78/90 patients (86.7%) and serious adverse events in 6/90 (6.7%); the latter were typical post-hepatectomy events unrelated to the study devices. No deaths were reported. Conclusions: InnoSEAL Plus DL was noninferior to TachoSil for achieving rapid intraoperative hemostasis during hepatectomy, with no unexpected safety concerns. This bioinspired hemostatic patch is an effective alternative to fibrin sealant, without the use of human-derived proteins.
- 12 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1087
Open AccessEfficacy and Safety of a Bioinspired Chitosan–Catechol/Gelatin Hemostatic Patch vs. TachoSil in Hepatectomy: A Randomized Noninferiority Trial
Background/Objectives: Topical hemostatic biomaterials are used to control diffuse parenchymal bleeding during hepatectomy. TachoSil is a widely used standard fibrin sealant patch. We evaluated the efficacy and safety of InnoSEAL Plus DL, a novel bioinspired absorbable chitosan–catechol/gelatin hemostatic patch, compared with TachoSil. Methods: This multicenter, randomized, single-blind, active-controlled, parallel-group noninferiority trial enrolled adults undergoing hepatectomy who had persistent oozing from the hepatic transection surface despite primary hemostasis. Participants were randomized in a 1:1 ratio to receive InnoSEAL Plus DL or TachoSil. The primary endpoint was hemostatic success within 3 min of application, with a prespecified noninferiority margin of −19.4 percentage points (pp). Safety was assessed up to 30 days postoperatively. Results: Ninety patients were randomized (45 per group). In the per-protocol population, 3 min hemostatic success was achieved in 100.0% of both the InnoSEAL Plus DL (43/43) and TachoSil (41/41) groups. The risk difference was 0.0 pp, and the lower bound of the one-sided 97.5% confidence interval was −8.2 pp, confirming noninferiority. The mean time to hemostasis was similar between groups (1.2 vs. 1.3 min), and no intraoperative rebleeding occurred. Adverse events were reported in 78/90 patients (86.7%) and serious adverse events in 6/90 (6.7%); the latter were typical post-hepatectomy events unrelated to the study devices. No deaths were reported. Conclusions: InnoSEAL Plus DL was noninferior to TachoSil for achieving rapid intraoperative hemostasis during hepatectomy, with no unexpected safety concerns. This bioinspired hemostatic patch is an effective alternative to fibrin sealant, without the use of human-derived proteins.
- 5 March 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , E47-E48
Letter to the Editor: Interpreting living-donor liver transplantation outcomes in portal vein thrombosis
- 5 March 2026
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 32 (7) , E47-E48
Letter to the Editor: Interpreting living-donor liver transplantation outcomes in portal vein thrombosis
- 15 February 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (9) , 1332-1333
Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations
- 15 February 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (9) , 1332-1333
Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations
- 26 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3449-3450
Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
- 26 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3449-3450
Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
- Open Access
- 15 January 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (1) , 102183
Left-sided portal hypertension: Local venous congestion without ascites
- 15 January 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (1) , 102183
Open AccessLeft-sided portal hypertension: Local venous congestion without ascites
- 2 January 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (2) , 480-481
Reconsidering the Clinical Feasibility of Venous Grafts for Bile Duct Replacement
- 2 January 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (2) , 480-481
Reconsidering the Clinical Feasibility of Venous Grafts for Bile Duct Replacement
- 29 December 2025
- Published by Wiley in Liver International
- Vol. 46 (2) , e70504
Beyond Baseline Proteomics: Toward Clinically Actionable Risk Stratification in HBV ‐Related ACLF
- 29 December 2025
- Published by Wiley in Liver International
- Vol. 46 (2) , e70504
Beyond Baseline Proteomics: Toward Clinically Actionable Risk Stratification in HBV ‐Related ACLF